Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 4513

Original article / research
Year : 2017 | Month : October | Volume : 11 | Issue : 10 | Page : FC01 - FC05

Modification of First-line Antiretroviral Therapy in Treatment-naive, HIV Positive Patients

Smita Shenoy, Dhairya Shrivastava, Chaithanya Malalur, Muralidhar Varma, Sushil Kiran Kunder, Avinash Arivazhahan, Kavitha Saravu

1. Additional Professor, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. 2. Intern, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. 3. Medical advisor, Biochem Pharmaceuticals (Zydus Cadila), Mumbai, Maharashtra, India. 4. Associate Professor, Department of Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. 5. Postgraduate, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. 6. Postgraduate, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. 7. Professor, Department of Medicine, Kasturba Medical College; Coordinator, Manipal McGill Center for Infectious Diseases, Manipal, Karnataka, India.

Correspondence Address :
Dr. Chaithanya Malalur,
Medical advisor, Biochem Pharmaceuticals (Zydus Cadila), 1st floor, Ackruti Star, Opposite Ackruti Center Point,
MIDC central road, Andheri East, Mumbai - 400093, Mumbai, Maharashtra, India.
E-mail: cmalalur@gmail.com

Abstract

Introduction: Modification of initial Antiretroviral Therapy (ART) program is an important issue in HIV infected patients as the number of ART regimens available is limited. Hence, there is a need to understand the factors that affect modification and therefore, the durability of the initial antiretroviral regimen.

Aim: To study the type of modification of first line ART in treatment-naive HIV positive patients and factors influencing it.

Materials and Methods: A retrospective observational study was carried out in the HIV clinic of a tertiary care hospital, using data obtained from the case records of the subjects who were initiated on ART between January 2012 to December 2014.Data on patient baseline characteristics, proportion of patients who required modification, type and time of modification was collected. The determinants of time to modification were analysed using Chisquare test. Binomial logistic regression was utilized to assess independent risk factors for change in regimen.

Results: Out of 200 case records analysed, 54 patients had to undergo a modification in their initial regimen. The mean age of patients was 44.68 ± 11.31 years. Majority of the patients were males. The most common reason for modification was Adverse Drug Reactions (ADRs) (79.63%) followed by treatment failure (9.25%). In 85.18% cases, modification involved substitution. Occurrence of ADRs and non-tenofovir based first-line regimens were associated with higher likelihood of substitution in regimen (p<0.05).The median time (IQR) to modification was 173 (152.25, 293.50) days.

Conclusion: ADRs and the use of non-tenofovir based regimens resulted in significantly higher rates of modification of antiretroviral therapy. There should be monitoring of patients on ART to detect ADRs at the earliest and to obtain increased use of single tablet containing tenofovir based regimen to improve durability of first line regimens.

Keywords

Adverse drug reactions, AIDS, Durability, Tenofovir

How to cite this article :

Smita Shenoy, Dhairya Shrivastava, Chaithanya Malalur, Muralidhar Varma, Sushil Kiran Kunder, Avinash Arivazhahan, et al.. MODIFICATION OF FIRST-LINE ANTIRETROVIRAL THERAPY IN TREATMENT-NAIVE, HIV POSITIVE PATIENTS. Journal of Clinical and Diagnostic Research [serial online] 2017 October [cited: 2017 Nov 19 ]; 11:FC01-FC05. Available from
http://jcdr.net/back_issues.asp?issn=0973-709x&year=2017&month=October&volume=11&issue=10&page=FC01-FC05&id=10735

DOI and Others

DOI: 10.7860/JCDR/2017/27311.10735

Date of Submission: Feb 06, 2017
Date of Peer Review: Mar 18, 2017
Date of Acceptance: Jul 13, 2017
Date of Publishing: Oct 01, 2017

FINANCIAL OR OTHER COMPETING INTERESTS: None.

JCDR is now Monthly and more widely Indexed .
  • PubMed Central® (PMC)New
  • Academic Search Complete Database
  • Chemical Abstracts Service
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhostNew
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Open J-Gate
  • Popline (reproductive health literature)
  • SCOPUS
  • www.omnimedicalsearch.com